A
AmbioPharm
AmbioPharm, Inc (APi) has developed a new business model responsive to an accelerating trend in our industry
About AmbioPharm
AmbioPharm, founded in 2005 and headquartered in North Augusta, South Carolina, is a global Contract Development and Manufacturing Organization (CDMO) specializing in peptide manufacturing. The company focuses on developing highly efficient processes for peptide-based Active Pharmaceutical Ingredients (APIs) at scales ranging from small to very large. AmbioPharm serves a diverse clientele, including pharmaceutical companies and biotech firms, providing them with tailored peptide manufacturing solutions. The company operates in the pharmaceutical and biotechnology markets, leveraging its extensive manufacturing capabilities and FDA-inspected facilities to ensure high-quality production standards.
AmbioPharm's business model revolves around offering comprehensive peptide manufacturing services, from development to large-scale production. The company generates revenue through contract manufacturing agreements, where clients pay for the development and production of peptide APIs. This model allows AmbioPharm to handle projects of varying sizes and complexities, making it a versatile partner in the peptide manufacturing industry.
Under the leadership of CEO Brian Gregg, who brings extensive experience from his tenure at Bachem, AmbioPharm continues to drive business and operational growth. The company is committed to diversity and inclusion, promoting a culture that values cooperation with the communities it serves.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2005
- Headquarters
- North Augusta, United States
- Employees
- 166
- Open positions
- 12
- Dealroom signal
- 37.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | May 2026 | $0 | — | CordenPharma | ↗ |
| GROWTH EQUITY VC✓Equity / VC | Sep 2018 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for AmbioPharm is 39K monthly website visits, up 95% over the last three months. AmbioPharm's team grew 1.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
MVM Life Science Partners
Other known investors3 additional known investors
CordenPharma- CCCarlyle Cardinal Ireland - CCI
The Carlyle Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AmbioPharm on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AmbioPharm’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.